Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, Inc. (Nasdaq: ATRC) has received regulatory approval from China's National Medical Products Administration (NMPA) to market and sell several models of its AtriClip® Left Atrial Appendage (LAA) Exclusion System. This innovative device is designed to exclude and electrically isolate the LAA during cardiac surgery, addressing a major source of blood clots in patients with atrial fibrillation (Afib).
The approval marks a significant milestone in AtriCure's global expansion strategy, opening up a substantial market opportunity in China. The company plans to partner with leading medical institutions and professionals in China to provide comprehensive training and support. AtriClip devices have been successfully used in over 550,000 patients worldwide, demonstrating robust clinical data on safety and efficacy.
AtriCure (Nasdaq: ATRC) will announce its second quarter 2024 financial results on July 30, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. A webcast will be hosted at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested individuals can register online, and both live and replay versions of the webcast will be accessible at AtriCure's investor relations site.
AtriCure, a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 2024 Leerink Partners Healthcare Crossroads Conference.
A fireside chat with AtriCure’s management is scheduled for Wednesday, May 29, 2024, at 10:40 a.m. Central Time. The live audio webcast will be accessible via the 'Investors' section of the company’s website.
AtriCure, Inc. reported first-quarter 2024 financial results, with worldwide revenue of $108.9 million, a 16.4% increase year over year. The U.S. revenue was $90.2 million, up 15.4% from first quarter 2023. International revenue increased by 21.5% to $18.6 million. Gross profit was $81.3 million with a gross margin of 74.7%. Loss from operations was $10.9 million. Adjusted EBITDA was $2.8 million. Full-year 2024 revenue is projected to be $459 million to $466 million, with adjusted EBITDA expected to be $26 million to $29 million.
AtriCure, Inc. (ATRC) will be participating in the 2024 Bank of America Securities Healthcare Conference. The company is known for its innovative surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. The management will present on May 14, 2024, at 10:15 a.m. PDT.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.